Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.48 |
| ▸ | HPN | P05981 | 1/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | PROC | P04070 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814838 | 0.80 | PRMT6 (0.46) | F10 | |
| SCHEMBL27495114 | 0.79 | PRSS1 (0.51) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL27603657 | 0.77 | HPGD (0.64) | — | |
| SCHEMBL11021735 | 0.77 | HPGD (0.64) | — | |
| SCHEMBL24322934 | 0.77 | F10 (0.58) | F10PLGPROCF2 | |
| SCHEMBL24323873 | 0.77 | F10 (0.58) | F10PLGPROCF2 | |
| SCHEMBL27479044 | 0.76 | L3MBTL1 (0.51) | F10PRSS1PRSS2PRSS3HPN | |
| Hydrochloric Acid SCHEMBL6872103 | 0.76 | HPGD (0.62) | — | |
| Hydrochloric Acid SCHEMBL5412784 | 0.76 | HPGD (0.62) | — | |
| SCHEMBL7419660 | 0.76 | PRSS1 (0.51) | F10PRSS1PRSS2PRSS3HPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | F10 1781/4885PRSS1 112/4885PRSS2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.